105 related articles for article (PubMed ID: 7226124)
1. Chemotherapy vs. chemoimmunotherapy with methanol extraction residue of Bacillus Calmette-Guerin (MER) in advanced breast cancer: a randomized trial by the Piedmont Oncology Association.
Muss HB; Richards F; Cooper MR; White DR; Jackson DV; Stuart JJ; Howard V; Shore A; Rhyne AL; Spurr CL
Cancer; 1981 May; 47(9):2295-301. PubMed ID: 7226124
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG.
Britell JC; Ahmann DL; Bisel HF; Frytak S; Ingle JN; Rubin J; O'Fallon JR
Cancer Clin Trials; 1979; 2(4):345-50. PubMed ID: 394870
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy-radiotherapy with and without the methanol-extraction residue of Bacillus Calmette-Guerin (MER) in small cell carcinoma of the lung: a prospective randomized trial of the Piedmont Oncology Association.
Jackson DV; Paschal BR; Ferree C; Richards F; Muss HB; Cooper MR; White DR; Stuart JJ; Spurr CL; Wells B; Sartiano G; McFarland J; McCulloch J
Cancer; 1982 Jul; 50(1):48-52. PubMed ID: 6282434
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: a prospective randomized study for the Piedmont Oncology Association.
Richards F; Howard V; Shore A; Muss HB; White DR; Jackson DV; Cooper MR; Bearden J; Stuart JJ; Sartiano G; Rhyne AL; Spurr CL
Cancer; 1981 Jun; 47(12):2827-32. PubMed ID: 6266642
[TBL] [Abstract][Full Text] [Related]
6. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma.
Blumenschein GR; Hortobagyi GN; Richman SP; Gutterman JU; Tashima CK; Buzdar AU; Burgess MA; Livingston RB; Hersh EM
Cancer; 1980 Feb; 45(4):742-9. PubMed ID: 6986970
[TBL] [Abstract][Full Text] [Related]
7. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
Cancer; 1979 Apr; 43(4):1225-33. PubMed ID: 445325
[TBL] [Abstract][Full Text] [Related]
8. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.
Hortobagyi GN; Yap HY; Blumenschein GR; Gutterman JU; Buzdar AU; Tashima CK; Hersh EM
Cancer Treat Rep; 1978 Nov; 62(11):1685-92. PubMed ID: 728894
[TBL] [Abstract][Full Text] [Related]
9. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole.
Hortobagyi GN; Gutterman JU; Blumenschein GR; Yap HY; Buzdar AU; Tashima CK; Burgess MA; Hersh EM
Cancer; 1979 Mar; 43(3):1112-22. PubMed ID: 427716
[TBL] [Abstract][Full Text] [Related]
10. Effects of methanol extraction residue of Bacillus calmette-Guérin in humans.
Perloff M; Holland JF; Lumb GJ; Bekesi JG
Cancer Res; 1977 Apr; 37(4):1191-6. PubMed ID: 321117
[TBL] [Abstract][Full Text] [Related]
11. MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study.
Vinciguerra V; Coleman M; Pajak TF; Rafla S; Stutzman L; Gomez G; Weil M; Brunner K; Cuttner J; Nissen N; Leventhal B; Gottlieb A
Cancer Clin Trials; 1981; 4(2):99-105. PubMed ID: 7018726
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy in advanced neuroblastoma.
Necheles TF; Rausen AR; Kung FH; Pochedly C
Cancer; 1978 Apr; 41(4):1282-8. PubMed ID: 638992
[TBL] [Abstract][Full Text] [Related]
13. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association.
Muss HB; Richards F; Jackson DV; Cooper MR; White DR; Stuart JJ; Ramseur W; Christian RM; Wells HB; Pope E; Spurr CL
Cancer; 1982 Dec; 50(11):2269-74. PubMed ID: 6754062
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
[TBL] [Abstract][Full Text] [Related]
15. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial.
Buzdar AU; Blumenschein GR; Smith TL; Powell KC; Hortobagyi GN; Yap HY; Schell FC; Barnes BC; Ames FC; Martin RG
Cancer; 1984 Feb; 53(3):384-9. PubMed ID: 6362814
[TBL] [Abstract][Full Text] [Related]
17. Treatment of lung cancer by radiotherapy, chemotherapy, and methanol extraction residue of BCG (MER): clinical and immunological studies.
Robinson E; Bartal A; Cohen Y; Haasz R; Mekori T
Cancer; 1977 Sep; 40(3):1052-9. PubMed ID: 902232
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.
Gutterman JU; Cardenas JO; Blumenschein GR; Hortobagyi G; Burgess MA; Livingston RB; Mavligit GM; Freireich EJ; Gottlieb JA; Hersh EM
Br Med J; 1976 Nov; 2(6046):1222-5. PubMed ID: 791447
[TBL] [Abstract][Full Text] [Related]
19. A preliminary study of cyclophosphamide (NSC-26271), adriamycin (NSC-123127), imidazole carboxamide (NSC-45388), and actinomycin D (NSC-3053) with or without MER-BCG in patients with advanced sarcomas.
Creagan ET; Edmonson JH; Hahn RG; Ahmann DL; Bisel HF; Eagan RT
Med Pediatr Oncol; 1978; 4(1):85-6. PubMed ID: 625266
[TBL] [Abstract][Full Text] [Related]
20. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
Hortobagyi GN; Gutterman JU; Blumenschein GR; Tashima CK; Burgess MA; Einhorn L; Buzdar AU; Richman SP; Hersh EM
Cancer; 1979 Nov; 44(5):1955-62. PubMed ID: 387212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
